Retatrutide

Triple Receptor Agonism and the Next Generation of Metabolic Medicine

PROPeptides Foundations Program

The development of semaglutide demonstrated that activating the GLP-1 receptor could produce substantial weight loss while improving blood glucose control and cardiovascular health. Tirzepatide advanced this concept further by combining GLP-1 receptor activation with glucose-dependent insulinotropic polypeptide (GIP), producing even greater reductions in body weight and metabolic risk factors.

Researchers then asked another important question:

Could obesity be treated even more effectively by activating a third metabolic pathway?

That question led to the development of retatrutide, the first investigational medication specifically engineered to activate three separate hormone receptors simultaneously:

  • Glucagon-like peptide-1 (GLP-1)

  • Glucose-dependent insulinotropic polypeptide (GIP)

  • Glucagon

Rather than focusing exclusively on reducing appetite, retatrutide attempts to influence both sides of the energy balance equation by decreasing energy intake while simultaneously increasing energy expenditure.

This represents an important evolution in obesity medicine. Instead of targeting hunger alone, triple agonist therapy seeks to more closely replicate the complex hormonal communication that naturally regulates body weight and metabolism.

Although retatrutide remains an investigational medication at the time of this writing, early clinical studies have generated significant interest because of the magnitude of weight loss observed and the potential implications for the future of metabolic medicine.

Why Add Glucagon?

Most people recognize glucagon as the hormone that raises blood sugar during fasting.

That description is accurate—but incomplete.

Glucagon plays a much broader physiological role than simply opposing insulin. During periods of fasting, exercise, or increased metabolic demand, glucagon helps coordinate the mobilization and utilization of stored energy.

Its actions include:

  • Stimulating hepatic glucose production

  • Promoting lipolysis (fat breakdown)

  • Increasing fatty acid oxidation

  • Supporting ketone production during prolonged fasting

  • Increasing resting energy expenditure

  • Regulating amino acid metabolism

These effects evolved to help humans survive periods of limited food availability by making stored energy accessible to the body.

Historically, glucagon receptor activation was considered an undesirable therapeutic target because increasing glucagon alone could worsen hyperglycemia.

The key insight came when researchers realized that simultaneous activation of GLP-1 could offset glucagon's glucose-raising effects while preserving many of its favorable metabolic actions.

This combination opened the door to an entirely new therapeutic strategy.

The Biology of Triple Agonism

Retatrutide combines three complementary physiological pathways into a single engineered peptide.

Each receptor contributes distinct metabolic effects.

GLP-1 contributes primarily to:

  • Reduced appetite

  • Earlier satiety

  • Slower gastric emptying

  • Increased glucose-dependent insulin secretion

  • Reduced glucagon secretion during meals

GIP contributes to:

  • Enhanced insulin responsiveness

  • Improved metabolic flexibility

  • Favorable nutrient partitioning

  • Central appetite regulation

  • Potential effects on adipose tissue remodeling

Glucagon contributes to:

  • Increased energy expenditure

  • Greater fat oxidation

  • Increased lipid utilization

  • Enhanced hepatic metabolic activity

  • Increased metabolic flexibility during fasting

Rather than competing with one another, these pathways appear to complement each other.

GLP-1 reduces caloric intake.

Glucagon increases energy utilization.

GIP may improve metabolic efficiency and insulin responsiveness.

Together, they produce a broader physiological response than any single pathway alone.

Energy Intake vs. Energy Expenditure

Many weight-loss medications primarily influence one side of the energy balance equation:

Calories consumed

Retatrutide appears to influence both.

On one side, activation of GLP-1 and GIP reduces appetite, promotes earlier satiety, and decreases spontaneous caloric intake.

On the other, glucagon receptor activation may increase resting energy expenditure and promote greater utilization of stored fat as an energy source.

This distinction is important because many individuals who lose weight experience adaptive thermogenesis, a phenomenon in which resting metabolic rate decreases as body weight declines. This reduction in energy expenditure is one reason long-term weight maintenance can be challenging.

Although research is ongoing, triple agonist therapy may partially counteract some of these adaptive responses by maintaining higher rates of energy utilization.

The extent to which this contributes to long-term clinical outcomes remains an active area of investigation.

What Have Clinical Trials Shown?

The most widely discussed clinical data come from a Phase II randomized trial evaluating retatrutide in adults with obesity or overweight.

Participants received once-weekly injections alongside lifestyle intervention for 48 weeks.

The results attracted considerable attention because of the magnitude of weight reduction observed.

At the highest dose studied:

  • Average weight loss approached 24% of baseline body weight at 48 weeks.

  • Weight loss had not clearly plateaued by the end of the study, suggesting additional reductions might occur with longer treatment.

  • Significant improvements were observed in waist circumference, glycemic measures, blood pressure, and other cardiometabolic markers.

These findings represent some of the largest average weight reductions reported for any pharmacologic therapy in obesity.

However, it is important to recognize that Phase II trials are designed to evaluate safety, dosing, and preliminary efficacy. Larger Phase III trials are necessary to confirm long-term effectiveness, durability, and safety across broader patient populations.

Potential Advantages

If ongoing studies continue to demonstrate favorable outcomes, triple agonist therapy may offer several theoretical advantages.

These include:

Greater Weight Loss

Early clinical trials suggest greater average reductions in body weight compared with previous incretin-based therapies, although direct comparisons between separate clinical trials should always be interpreted cautiously.

Improved Fat Oxidation

Glucagon receptor activation appears to increase the body's utilization of stored fat for energy, potentially complementing the appetite-reducing effects of GLP-1.

Increased Energy Expenditure

Unlike therapies that primarily reduce caloric intake, triple agonists may also increase energy expenditure.

This remains one of the most scientifically interesting aspects of retatrutide and continues to be investigated.

Broad Metabolic Effects

Because all three receptors influence multiple organ systems, retatrutide may produce improvements extending beyond weight loss alone, including glucose regulation, liver fat, lipid metabolism, and cardiovascular risk factors.

Many of these potential benefits are still being evaluated in ongoing clinical research.

Safety Considerations

Because retatrutide remains investigational, its long-term safety profile continues to evolve.

The most commonly reported adverse effects in clinical trials have generally resembled those seen with other incretin therapies and include:

  • Nausea

  • Vomiting

  • Diarrhea

  • Constipation

  • Abdominal discomfort

  • Reduced appetite

These symptoms were typically dose-dependent and occurred most frequently during dose escalation.

Whether glucagon receptor activation contributes additional long-term considerations remains an area of ongoing investigation.

As with all investigational therapies, conclusions regarding long-term safety should await completion of large Phase III clinical trials and post-marketing surveillance if regulatory approval is obtained.

Where Does Retatrutide Fit?

Retatrutide illustrates an important trend in modern peptide medicine.

Rather than developing increasingly potent versions of a single hormone, researchers are designing therapies that more closely resemble the body's naturally integrated hormonal communication networks.

Future metabolic medications may continue this progression by incorporating additional pathways involved in:

  • Energy sensing

  • Mitochondrial function

  • Brown adipose tissue activation

  • Muscle preservation

  • Nutrient partitioning

  • Inflammation

  • Cellular aging

Triple agonist therapy therefore represents not only a promising medication but also a glimpse into the future direction of metabolic medicine.

Looking Ahead

GLP-1 receptor agonists, dual incretin therapies, and triple agonists all focus primarily on improving appetite regulation and metabolic health.

However, not every peptide used in body composition management works through incretin biology.

Several additional peptides—including tesamorelin, MOTS-c, and AOD-9604—target different physiological systems involved in visceral fat metabolism, growth hormone signaling, mitochondrial function, and cellular energy production.

The next section explores these therapies, the evidence supporting their use, and how they differ fundamentally from GLP-1–based medications.

Key References

  1. Jastreboff AM, et al. Triple–Hormone Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023.

  2. Coskun T, et al. Triple Hormone Receptor Agonism in Metabolic Disease. Cell Metabolism. 2022.

  3. Finan B, Müller TD, DiMarchi RD. Next-Generation Peptide Therapeutics for Obesity. Nature Reviews Drug Discovery. 2021.

  4. Müller TD, et al. Glucagon Biology and Therapeutic Applications. Nature Reviews Drug Discovery. 2017.

  5. Campbell JE, Drucker DJ. Incretin Physiology and Therapeutic Implications. Cell Metabolism. 2020.

→ Continue to: Additional Metabolic Peptides